We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

110 hedge funds and large institutions have $300M invested in Rigel Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $227M → $300M (+$73.5M)

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

10% more funds holding

Funds holding: 100 → 110 (+10)

52% less call options, than puts

Call options by funds: $579K | Put options by funds: $1.19M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
110
Holders Change
+10
Holders Change %
+10%
% of All Funds
3.18%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
26
Increased
35
Reduced
30
Closed
15
Calls
$579K
Puts
$1.19M
Net Calls
-$615K
Net Calls Change
-$766K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$15M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.56M
3
DCM
Driehaus Capital Management
Illinois
+$2.88M
4
PC
Polar Capital
United Kingdom
+$1.85M
5
BC
Broadfin Capital
New York
+$1.78M

Top Sellers

1
BI
BVF Inc
California
-$19.1M
2
VAM
Visium Asset Management
New York
-$5.03M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.81M
4
Millennium Management
Millennium Management
New York
-$3.63M
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
26
PointState Capital
New York
$1.94M +$1.78M +50,000 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.9M +$155K +4,359 +10%
BBA
28
Baker Bros. Advisors
New York
$1.87M -$64.3K -1,803 -4%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$1.68M +$51.2K +1,437 +3%
SAM
30
Senzar Asset Management
New York
$1.64M +$1.08M +30,170 +252%
Deutsche Bank
31
Deutsche Bank
Germany
$1.57M -$365K -10,225 -20%
BA
32
BlackRock Advisors
Delaware
$1.56M +$1.22M +34,247 +578%
TCIM
33
TIAA CREF Investment Management
New York
$1.49M -$38.6K -1,084 -3%
Jacobs Levy Equity Management
34
Jacobs Levy Equity Management
New Jersey
$1.44M -$341K -9,563 -21%
TC
35
TFS Capital
Pennsylvania
$1.42M -$417K -11,700 -24%
RA
36
Royce & Associates
New York
$1.2M +$1.43K +40 +0.1%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.18M -$1.11M -31,243 -51%
BIM
38
BlackRock Investment Management
Delaware
$1.15M -$4.49K -126 -0.4%
AllianceBernstein
39
AllianceBernstein
Tennessee
$1.15M -$927 -26 -0.1%
TI
40
Turner Investments
Pennsylvania
$1.15M +$466K +13,083 +79%
Charles Schwab
41
Charles Schwab
California
$935K +$20.3K +570 +2%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$863K -$48.1K -1,350 -6%
Goldman Sachs
43
Goldman Sachs
New York
$857K +$128K +3,597 +19%
Renaissance Technologies
44
Renaissance Technologies
New York
$817K -$3.35M -93,961 -82%
Neuberger Berman Group
45
Neuberger Berman Group
New York
$679K +$624K +17,500 New
BG
46
BlackRock Group
United Kingdom
$639K -$4.88K -137 -0.8%
RFC
47
Russell Frank Company
Washington
$638K -$120K -3,361 -15%
Los Angeles Capital Management
48
Los Angeles Capital Management
California
$626K +$575K +16,131 New
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$613K +$563K +15,792 New
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$612K – – –
1
2
3 4 5

RIGL Hedge Fund Activity: Q1 2014 in Review

110 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2014, worth a combined $300M — up 32% from $227M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RIGL positions and 15 closed out — a net gain of 11 holders — while 35 added to existing stakes and 30 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $15M. The largest seller was BVF Inc, cutting an estimated $19.1M.

  • 110 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2014, up from 100 in Q4 2013.
  • Funds reported $300M of Rigel Pharmaceuticals stock for Q1 2014, up 32% quarter-over-quarter.
  • 26 funds opened new Rigel Pharmaceuticals positions in Q1 2014 and 15 closed out, a net change of +11 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $15M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2014 was BVF Inc, an estimated $19.1M sold.

Based on aggregated 13F filings for Q1 2014.